Methotrexate
Methotrexate plus pegloticase improves gout evaluations, patient outcomes at 1 year
Concomitant use of methotrexate and pegloticase resulted in “meaningful” improvements in joint assessments and patient-reported outcomes at 12 months in uncontrolled gout, according to data presented at the EULAR 2021 Virtual Congress.
VIDEO: COVID-19 vaccine recommendations for patients with psoriasis
In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, spoke with Healio about COVID-19 vaccination among patients with psoriasis.
Patients more likely to achieve sustained RA remission on biological vs. triple therapy
Patients with rheumatoid arthritis who start biological therapy after failing methotrexate are about two times more likely to be adherent and achieve sustained remission at 1 and 2 years than with triple therapy, according to data.
Liver disease may be more common in patients on methotrexate for psoriatic disease
Upadacitinib matches, exceeds adalimumab for improving patient-reported outcomes in RA
Upadacitinib is equivalent or superior to adalimumab in improving patient-reported outcomes among those with rheumatoid arthritis and an inadequate response to methotrexate, according to data published in Rheumatology.
Ixekizumab effective in psoriatic arthritis up to 1 year regardless of methotrexate use
Ixekizumab is efficacious in patients with psoriatic arthritis for up to 1 year, with or without concomitant methotrexate use, according to data published in Arthritis Research & Therapy.
Filgotinib improves RA symptoms in patients with inadequate methotrexate response
Filgotinib improves rheumatoid arthritis signs, symptoms and physician function, and inhibits radiographic progression, all while being well-tolerated in patients with an insufficient response to methotrexate, according to data.
TNF inhibitors, methotrexate may not worsen outcomes in COVID-19
Patients being treated with tumor necrosis factor inhibitors or methotrexate who acquired COVID-19 did not experience elevated hospitalization or mortality rates, according to a study.
Upadacitinib monotherapy improves patient-reported outcomes in MTX-naïve, refractory RA
Upadacitinib monotherapy improves patient-reported pain, physical function, morning stiffness and other measures in those with rheumatoid arthritis who never received, or had an inadequate response to, methotrexate, according to data.